SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005; 100: 24782485.
    Direct Link:
  • 2
    Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007; 132: 6675; quiz 432–433.
  • 3
    Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353: 24622476 [erratum: N Engl J Med 2006;354:2200].
  • 4
    Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut. 2007; 56: 453455.
  • 5
    Kane S, Lu F, Kornbluth A, et al. Controversies in mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2009; 15: 796800.
  • 6
    Frøslie KF, Jahnsen J, Moum BA, et al; IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007; 133: 412422.
  • 7
    Hanai H, Watanabe F, Takeuchi K, et al. Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin Gastroenterol Hepatol. 2003; 1: 2835.
  • 8
    Suzuki Y, Yoshimura N, Saniabadi AR, et al. Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci. 2004; 49: 565571.
  • 9
    Naganuma M, Funakoshi S, Sakuraba A, et al. Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm Bowel Dis. 2004; 10: 251257.
  • 10
    Hanai H, Watanabe F, Yamada M, et al. Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digestion. 2004; 70: 3644.
  • 11
    Yamamoto T, Umegae S, Kitagawa T, et al. Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study. Aliment Pharmacol Ther. 2004; 20: 783792.
  • 12
    Kanke K, Nakano M, Hiraishi H, et al. Clinical evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig Liver Dis. 2004; 36: 811817.
  • 13
    Yamamoto T, Saniabadi AR, Umegae S, et al. Impact of selective leukocytapheresis on mucosal inflammation and ulcerative colitis: cytokine profiles and endoscopic findings. Inflamm Bowel Dis. 2006; 12: 719726.
  • 14
    Yamamoto T, Saniabadi AR, Maruyama Y, et al. Factors affecting clinical and endoscopic efficacies of selective leucocytapheresis for ulcerative colitis. Dig Liver Dis. 2007; 39: 626633.
  • 15
    Sakuraba A, Motoya S, Watanabe K, et al. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol. 2009; 104: 29902995.
  • 16
    Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987; 92: 19841988.
  • 17
    Saniabadi AR, Hanai H, Takeuchi K, et al. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Therap Apher Dial. 2003; 7: 4859.
  • 18
    Sands BE, Sandborn WJ, Feagan B, et al; Adacolumn Study Group. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology. 2008; 135: 400409.
  • 19
    Meucci G, Fasoli R, Saibeni S, et al. Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: preliminary results of a prospective, multicenter study. Gastroenterology. 2006; 130: A1302.
  • 20
    Muratov V, Lundahl J, Ulfgren AK, et al. Down-regulation of interferon-gamma parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease: a 12-month follow-up study. Int J Colorectal Dis. 2006; 21: 493504.
  • 21
    Domènech E, Hinojosa J, Esteve-Comas M, et al. Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther. 2004; 20: 13471352.
  • 22
    Maiden L, Takeuchi K, Baur R, et al. Selective white cell apheresis reduces relapse rates in patients with IBD at significant risk of clinical relapse. Inflamm Bowel Dis. 2008; 14: 14131418.